Pyxis Oncology
PYXS
99 hedge funds and large institutions have $49.2M invested in Pyxis Oncology in 2024 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 19 closing their positions.
1,884% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $80K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
8% more funds holding
Funds holding: 92 → 99 (+7)
6.13% more ownership
Funds ownership: 46.93% → 53.06% (+6.1%)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
53% less capital inflows, than outflows
Capital inflows: $13.3M | Capital outflows: $28.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.1M |
| 2 |
Palo Alto Investors
Palo Alto,
California
|
+$2.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.21M |
| 4 |
BlackRock
New York
|
+$1.1M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$632K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$15.4M |
| 2 |
Blue Owl Capital Holdings
New York
|
-$4.13M |
| 3 |
Stempoint Capital
New York
|
-$3.12M |
| 4 |
Ikarian Capital
Dallas,
Texas
|
-$993K |
| 5 |
Perceptive Advisors
New York
|
-$923K |
PYXS Hedge Fund Activity: Q4 2024 in Review
99 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2024, worth a combined $49.2M — down 52% from $102M a quarter earlier.
Fund positioning in PYXS was balanced in Q4 2024: 19 funds opened new positions, 19 closed out, 33 added to existing stakes and 18 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.1M. The largest seller was Deep Track Capital, exiting entirely with an estimated $15.4M sold.
- 99 institutional investors held Pyxis Oncology (PYXS) as of Q4 2024, up from 92 in Q3 2024.
- Funds reported $49.2M of Pyxis Oncology stock for Q4 2024, down 52% quarter-over-quarter.
- 19 funds opened new Pyxis Oncology positions in Q4 2024 and 19 closed out, a net change of 0 holders.
- The largest Pyxis Oncology buyer in Q4 2024 was Millennium Management, an estimated $3.1M added.
- The largest Pyxis Oncology seller in Q4 2024 was Deep Track Capital, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2024.